Galenica records solid growth in 2024

In 2024, Galenica AG reported sales growth of 4.7% to CHF 3,922 million. This performance outpaces the Swiss pharmaceutical market growth of 3.5% according to IQVIA. The increase is attributed to strong momentum in the second half of the year, which saw a 6.7% increase driven by market share gains. Organic growth in pharmacies played a key role, although hampered by high generic sales and low influenza activity.

The "Products & Care" segment developed favourably, recording sales of CHF 1,700.2 million (+3.9%). The "Logistics & IT" segment also saw notable growth to CHF 3,240.7 million (+5.3%). Galenica confirms its outlook for the year, predicting an increase in EBIT of 8% to 11%.